VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study
Titel:
VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study
Auteur:
Metcalf, R. Laban, S. Kristensen, C.A. Ciuleanu, T-E. BraƱa, I. Soria Rivas, A. Dieter, S.M. Bols, A. Forster, M.D. Covela, M.R. Christian, J. Vogl, F.D. Mueller, C. Triebel, F.